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SYMBOLS AND ABBREVIATIONS 
 
m  magnetic moment 
r  spin density 
B0  main magnetic field 
B1  RF field 
B1L  locking field 
CNR  contrast-to-noise ratio 
CSF  cerebrospinal fluid 
CT  x-ray computer assisted tomography 
CTAP  CT during arterial portography 
EMT  magnetization transfer effect 
ESL  spin lock effect 
f0  frequency 
FA  flip angle 
FISP  fast imaging with steady state free precession 
FLAIR  fluid attenuated inversion recovery 
FNB  fine needle biopsy 
FNH  focal nodular hyperplasia 
FOV  field of view 
fSE  fast spin echo 
Gd-BOPTA  gadolinium benzyloxypropionictetraacetic acid 
Gd-DOTA  gadolinium tetraazacyclododecanetetraacetic acid 
Gd-DTPA  gadolinium diethylenetriamine pentaacetic acid 
Gd-EOB-DTPA gadolinium-ethoxybenzyldiethylenetriaminepentaacetic acid 
GE  gradient echo 
HASTE  half-fourier acquisition single shot turbo spin echo 
HCC  hepatocellular carcinoma 
IR  inversion recovery 
MA  matrix 
Mn  manganese 
MnDPDP  manganese dipyridoxyl-diphosphate 
MRA  magnetic resonance angiography 
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MRI  magnetic resonance imaging 
MRS  magnetic resonance spectroscopy 
MT  magnetization transfer 
MTC  magnetization transfer contrast 
NEX  number of excitations 
NMR  nuclear magnetic resonance 
RES  reticuloendothelial system 
RF  radiofrequency 
ROI  region-of-interest 
SAR  specific absorption rate 
SD  standard deviation 
SEM  standard error of the mean 
SE  spin echo 
SI  signal intensity 
SIR  signal intensity ratio 
SL  spin lock 
SNR  signal-to-noise ratio 
SPIO  superparamagnetic iron oxide 
STIR  short inversion time inversion recovery 
T1  longitudinal relaxation time 
T1ρ  relaxation time in the rotating frame of reference 
T2  transverse relaxation time 
TA  time of acquisition 
TE  time to echo 
TI  inversion time 
TL  locking time 
TR  repetition time 
USPIO  ultrasmall superparamagnetic iron oxide 
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INTRODUCTION 
 
Liver is a common site for distant metastases of cancers originating from the colon and the breast. 
Liver cirrhosis is often complicated by hepatocellular carcinoma. Modern operative techniques and 
local therapies such as radiofrequency (RF) ablation are effective methods to treat liver metastases 
or primary hepatic malignancies (Fong et al., 1997; Gazelle et al., 2000). Therefore, the 
determination of liver lesion count, and the nature of the lesion are important. At present, the most 
accurate noninvasive method for the assessment of liver lesion count is magnetic resonance imaging 
(MRI). 
 
The contrast between tissues on MR images depends mainly on differencies in their T1 and T2 
relaxation times and proton densities. Basic techniques such as spin echo (SE) or gradient echo 
(GE) sequences can be used for imaging to obtain high contrast images. Additionally, there are a 
number of other methods to manipulate MR contrast in order to enhance signal differencies between 
normal and pathological tissues. 
 
The magnetization transfer (MT) technique in MRI was introduced in 1989 (Wolff and Balaban, 
1989). The method is based on saturating macromolecular spins with a dedicated irradiation 
radiofrequency (RF)-pulse, and observing the effects of the subsequent exchange processes. The 
signal of tissues with a high macromolecular content is reduced on MT images in comparison to the 
standard images. MT based tissue contrast may even more effectively be generated with the spin 
lock (SL) technique which probes tissue relaxation processes at very low magnetic field strengths 
while maintaining the high signal-to-noise ratio provided by the polarizing magnetic system 
(Sepponen et al., 1984). In a SL experiment, a preparation or locking pulse is applied before the 
signal collecting conventional imaging sequence. The multiple slice SL imaging technique was 
introduced in 1993 (Sepponen et al., 1993). 
 
Contrast agents are widely used in routine clinical MR imaging. Extracellular gadolinium chelates 
such as gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA) or gadolinium 
tetraazacyclododecanetetraacetic acid (Gd-DOTA) constitute the major group of MR contrast agents 
used today. Because of their unspecific nature with rapid extracellular distribution, fast imaging 
techniques and knowledge about the different enhancement patterns of liver lesions are essential. 
More recently, research has focused on the development of tissue-specific MR contrast agents with 
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a long imaging window due to their prolonged removal from the target-tissue. The accumulation of 
magnetically potent agents in normal hepatic parenchyma while leaving liver tumors unaffected 
increases the signal difference between tumors and normal liver, thus rendering lesions more 
conspicuous. Superparamagnetic iron oxide (SPIO) and manganese (II) N,N´-
dipyridoxylethylenediamine-N,N´-diacetate-5,5´-biphosphate or manganese dipyridoxyl-
diphosphate (MnDPDP) are examples of tissue-specific agents. 
 
In this thesis, a resistive 0.1T magnet and superconducting MR systems operating at 1.0T and 1.5T 
were used for evaluating patients with known or suspected focal liver lesions. The ability of the 
multiple slice SL technique in the generation of MT-like tissue contrast, and the potential of the 
multiple slice SL technique in the differentiation of hepatic hemangiomas and liver metastases were 
assessed (I, II). The benefit of tissue-specific contrast agents SPIO (III) and MnDPDP (IV) and 
SPIO in conjunction with Gd-DOTA in lesion detection (V) was also investigated. 
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REVIEW OF THE LITERATURE 
 
1. Image Contrast in MRI 
 
1.1 Basic principles 
 
There are two kinds of spin relaxations. The recovery of longitudinal magnetization is characterized 
by the relaxation time constant T1. The dissappearance of rotating (transverse) magnetization is 
characterized by the relaxation time constant T2. The contrast seen on MR images is generated 
mainly through differencies in these tissue T1 and T2 relaxation times and to a lesser degree, 
through tissue spin density (Wehrli et al., 1984). In addition to these intrinsic determinants of tissue 
contrast, there are a number of extrinsic factors that may be employed to modify image contrast. 
These include the strength of the main magnetic field (Rinck et al., 1988), sequence parameters such 
as repetition time (TR), echo time (TE) and flip angle (FA), the use of special imaging techniques 
such as MT or SL, and the use of MR contrast agents (Villafana, 1988). 
 
1.1.1 Spin echo sequence 
 
With spin echo (SE) technique, an initial excitation pulse at resonance is applied to tilt the spins 
around the axis of the excitatory magnetic field (B1). Longitudinal magnetization is reduced and 
transverse magnetization is generated but it starts to disappear rapidly because of spin dephasing. 
After a time period one half of TE, a refocusing pulse is applied and after another one half of TE an 
echo is produced. TE is the time from the excitatory pulse to center of the signal collection, and TR 
is the time between two excitations (between two excitatory pulses). 
 
The combination of selected TR and TE determines whether images have so-called T1- or T2-
weighting (Villafana 1988; Makow, 1989). T1-weighted SE images are acquired with a combination 
of short TR and short TE. Liver has a T1 relaxation time of approximately 550-700 ms at 1.5T 
(Thomsen et al., 1990; van Lom et al., 1991), 450 ms at 1.0T (Bottomley et al., 1984), and 200 ms 
at 0.1T (Kajander et al., 1996). By using the SE technique, T1-weighted images are obtained with a 
TR less than the liver T1 relaxation time. On T1-weighted images, fluid such as the content of a 
simple liver cyst has low signal intensity because of long T1 relaxation time, whereas fat appears 
bright due to short T1 relaxation time. 
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On T2-weighted MR images obtained with proper imaging parameters, tissues with long T2 
relaxation times such as simple liver cysts or hemangiomas appear bright. T2-weighted SE images 
are obtained with a long TE and with a long TR (Villafana, 1988; Makow, 1989). Liver T2 
relaxation time is approximately 45-60 ms (Goldberg et al., 1991). Therefore, with a TE of 90 ms or 
more, liver signal has decayed significantly. TR on the other hand should be long enough to allow 
recovery of tissue magnetization (at least three times tissue T1 relaxation time).  
 
1.1.2 Gradient echo sequence 
 
With gradient echo (GE) techniques, gradient inversions are employed in order to rephase the spins 
(Villafana, 1988). Generally, short TRs and TEs are employed. Also, small flip angles are utilized to 
take advantage of residual longitudinal magnetization to acquire images with high signal intensity 
despite of very short TRs. Flip angle affects image contrast in conjunction with TE. With a given 
TR, the use of a large FA and short TE, sequences produce predominantly T1-weighted images, and 
with the use of small FAs and a long TE, the images have predominantly T2-weighting (Wehrli, 
1987). 
 
1.1.3 Inversion recovery sequence 
 
With inversion recovery (IR) sequences, the magnetization of protons is initially flipped 180°. Then, 
the magnetization begins to recover, but after a time called inversion time (TI), a 90° RF pulse is 
applied, and regular signal collecting sequence follows. Because of tissue T1 dispersion i.e. tissue 
T1 relaxation time dependence on the main magnetic field (B0) strength (Koenig et al., 1984), the TI 
and TR used with the IR sequences should be correctly chosen according to B0 for the best contrast 
(Young et al., 1998). By adjusting the TI approximately to 0.7 times of tissue T1 relaxation time, it 
is possible to almost completely cancel signal from selected tissues (Bydder and Young, 1985). One 
widely used clinical IR application is the fluid attenuated inversion recovery (FLAIR) sequence for 
nulling the signal from cerebro-spinal fluid (CSF) for enhanced detection of brain white matter 
abnormalities (de Coene et al., 1992). 
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The short inversion time IR sequence (STIR) is a sequence with TI so short that the signal from fat 
is nulled (Bydder et al., 1985a and 1985b). With a long TE, the STIR technique possesses 
synergistic T1 and T2 contrast properties, and gives high signal for most pathological lesions such 
as liver metastases or hemangiomas that exhibit both long T1 and long T2 (Atlas et al., 1988). In 
clinical MRI, the STIR sequence has proved to be sensitive in the detection of focal liver 
lesions (Paling et al., 1988; Reinig et al., 1989). At 1.5T, it has been shown to be as sensitive as CT 
during arterial portography (CTAP) (Paulson et al., 1994). 
 
2. Methods to Improve Image Contrast: Radiofrequency Pulse Manipulation 
 
2.1 General considerations 
 
There are a number of extrinsic methods to improve contrast in MR images. Important clinical 
applications include the MT and the SL techniques. MT has been utilized in liver tumor imaging 
(Outwater et al., 1992; Kahn et al., 1993) as well as in the imaging of knee (Wolff et al., 1991), head 
and neck tumors (Markkola et al., 1996), spine (Finelli et al., 1994) and brain (Lundbom, 1992). It 
is also utilized in MR angiography (MRA) (Atkinson et al., 1994). The SL technique has been used 
in the MR imaging of muscle (Lamminen et al., 1993) and breast diseases (Santyr et al., 1989), in 
head and neck MR imaging (Markkola et al., 1996), in neuroradiology (Aronen et al., 1999), and in 
MR histology (Engelhardt and Johnson, 1996). 
 
2.2 Magnetization transfer technique 
 
The MT technique was first introduced as a method for producing additional contrast for MR 
imaging by Wolff and Balaban in 1989 (Wolff and Balaban, 1989). In tissues, there are freely 
moving protons in water molecules (Hf) and protons with restricted mobility (Hr) located in 
macromolecules. There is constant exchange of magnetizations between these proton pools due to 
dipole-dipole interactions (Koenig et al., 1978; Grad and Bryant, 1990). Tissue contrast in MT 
imaging technique is based on these exchange processes. MT utilizes often an off-resonance RF 
pulse for saturation of the magnetization of bound protons before the signal generating and 
collecting MR sequence. Due to exchange processes, the saturation of Hf is transferred to Hr. 
Therefore, there is a net reduction in the magnetization of Hf, and consecutively, a decrease in the 
strength of the collected signal. With tissues with high macromolecule content such as liver the 
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detected reduction in signal intensity is high while in tissues such as fat, the MT effect is minimal. 
The observed decline in signal intensity is therefore tissue-dependent (Niemi et al., 1992), which is 
the basis of the magnetization transfer contrast (MTC). 
 
2.3 Multiple slice spin lock technique 
 
The efficiency of relaxation mechanisms is known to increase when the main magnetic field 
decreases due to water-macromolecule interactions (Koenig et al., 1984). SL MR imaging technique 
utilizes the measurement of longitudinal relaxation at very low magnetic field strengths (far below 
0.01T). In an on-resonance SL experiment, the spins are first excited by a 90° RF pulse. Thereafter, 
a locking pulse (B1L) at resonance is implemented. The magnetization remains locked in the 
direction of B1L for the locking time (TL) period and thus, the relaxation occurs along the direction 
of B1L (Sepponen, 1992). This relaxation is characterized by the time constant T1ρ. The value of 
T1ρ depends on the strength of the locking field B1L (T1ρ dispersion) (Sepponen et al., 1986; 
Lamminen et al., 1993; Markkola et al., 1996). Typically, T1ρ is approximately T1 at very low 
magnetic field strengths, and close to T2 at field strengths of B0. It has been suggested that MT is 
the major source of relaxation at very low magnetic field strengths (Zhong et al., 1989; Grad et al., 
1990; Zhong et al., 1990; Koenig et al., 1993; Henkelman et al., 1993), and it has been 
demonstrated that T1ρ is sensitive to MT effects between mobile water protons and macromolecular 
protons in proteins. 
 
The multiple slice SL technique was introduced by Sepponen and co-workers in 1993 (Sepponen et 
al., 1993). This technique has been demonstrated to produce high contrast images with T1ρ 
weighting (Santyr et al., 1994). Locking pulses consisting of three sections are applied. First section 
tilts the magnetization 90° from the direction of the main magnetic field. Then, the locking period is 
followed and the magnetization is locked by B1L and the relaxation takes place. The magnetization 
is returned back to the direction of the main magnetic field by applying the third section. After the 
introduction of the locking pulse, the signal is collected by applying a conventional imaging 
sequence (Sepponen, 1992). Thus, high signal-to-noise is maintained with the use of the multiple 
slice SL method. 
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It has been suggested that in tissues with a high protein content such as liver, MT is the dominant 
relaxation mechanism detected with the SL technique (Zhong et al., 1989). MT imaging has been 
shown to be useful in the distinction between hepatic hemangiomas and liver metastases (Kahn et 
al., 1992; Outwater et al., 1992; Loesberg et al., 1993). Therefore, it can be expected that the SL 
technique may be used to obtain images with improved liver/lesion information when compared 
with conventional sequences. As the SL technique generates more efficiently MT based tissue 
contrast, and with the possibility of T1ρ dispersion through changing the locking field, the SL 
technique has theoretical advantages over the MT technique. 
 
3. Methods to Improve Image Contrast: MR Contrast Agents 
 
The purpose of contrast agents in liver MRI is to increase the signal difference between normal 
hepatic parenchyma and focal liver lesion, thus lowering the threshold for detection. Accurate 
delineation of pathological processes and improved lesion characterization potential are additional 
but equally important aims of contrast agent use. 
 
3.1 Basic principles of MR contrast agents 
 
A number of MR contrast agents have been developed. Basically, they can be divided into 
extracellular (unspecific) and cell-targeted (tissue-specific) agents depending on their 
biodistribution within the body. According to their physiologic behavior, they may be classified as 
extracellular, hepatobiliary, reticuloendothelial system (RES), blood pool and hybrid agents. The 
latter includes gadobenate dimeglumine (Gd-BOPTA) and gadolinium-
ethoxybenzyldiethylenetriaminepentaacetic acid (Gd-EOB-DTPA) which can be imaged in the 
extracellular and hepatocyte phases. Contrast agents alter tissue T1 and T2 relaxation rates to the 
extent that a measurable change in signal intensity is observed. Paramagnetic and 
superparamagnetic ions or compounds have such properties. 
 
Paramagnetic substances possess unpaired electrons, which have magnetic moments. When placed 
in an external magnetic field, these unpaired electrons align parallel to the field, thus reinforcing the 
external field. The mechanisms of paramagnetic contrast agents on proton relaxation have widely 
been studied. The magnitude of the magnetic interaction between a paramagnetic compound and 
neighboring water protons is proportional to the inverse of the distance raised to the sixth power 
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(1/r6). Thus, it is essential that water protons have access to the vicinity paramagnetic ions. In 
addition, the relaxation effect is proportional to the square of the magnetic moment. 
 
Superparamagnetism can occur if a crystal containing regions of unpaired spins are large enough 
(Bean and Livingstone, 1959). Such particles possess a net magnetic moment, which is by 
magnitude larger than the sum of its individual unpaired electrons. When placed in an external 
magnetic field the magnetic moments of these particles align parallel with the field. The magnetic 
moments of these particles are much greater than the magnetic moments of paramagnetic agents. 
Due to the inhomogeneities within the magnetic field caused by these particles, the nearby diffusing 
spins demonstrate rapid dephasing resulting in decreased signal intensity in clinical images. 
 
3.2 Gadolinium derivatives 
 
Gadolinium chelates were the first contrast agents available for clinical abdominal MR imaging 
(Carr et al., 1984). Paramagnetic gadolinium increases tissue relaxation rates. Tissues where it 
accumulates are seen brighter in the enhanced T1-weighted images than in the unenhanced images. 
Gadolinium chelates are extracellular contrast agents with pharmacokinetical characteristics similar 
to iodine contrast agents used with x-ray computer assisted tomography (CT) (Mahfouz and Hamm, 
1997). After intravenous injection, it rapidly accumulates both into the interstitium of normal liver 
and solid hepatic lesions. At a given time point their signal intensity may be equal. Therefore, fast 
imaging techniques with accurate timing are necessary when using extracellular contrast agents. 
Dynamic gadolinium-enhanced MRI has shown potential in the characterization of liver lesions 
(Mitchell et al., 1994) while the benefit in lesion detection is negligible (Hamm et al., 1992). 
 
3.3 Tissue-specific contrast agents 
 
In developing tissue-specific contrast agents for liver tumor imaging, the goal has been to produce 
agents that accumulate in normal tissue but not in focal lesions. The signal from normal liver 
changes while they have practically no effect on the signal acquired from e.g. metastatic liver 
deposits. The aim is that the signal difference, i.e. the contrast-to-noise ratios (CNR) of these lesions 
increase. Therefore, tissue-specific agents have the potential to decrease the detection threshold. 
Another advantage of liver-specific contrast agents is a long imaging window. Imaging may take 
place even several hours after the contrast agent injection. Also, the doses needed are much smaller 
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than with Gd-DTPA. In clinical MRI, three different tissue-specific contrast agents are currently 
available namely SPIO, MnDPDP and Gd-BOPTA. 
 
3.3.1 Superparamagnetic iron oxide 
 
Superparamagnetic iron oxide (SPIO) (Endorem, Guerbet, Paris, France) was the first tissue-
specific contrast agent introduced for liver MRI (Saini et al., 1987; Stark et al., 1988; Tsang et al., 
1988; Fretz et al., 1989; Weissleder et al., 1989). It is selectively targeted to the RES, and it 
accumulates in the Kupffer cells within the liver (Saini et al., 1987; Weissleder et al., 1989). The 
Kupffer cells constitute about 80% of the RES. Thus, of a given dose of SPIO a large part 
eventually ends up within liver parenchyma. SPIO is a superparamagnetic contrast agent. SPIO 
particles are large enough to act as independent magnetic domains (Stark, 1990). They create 
magnetic fields around themselves when placed within an external magnetic field. Therefore, they 
promote small field inhomogeneities within the external magnetic field and hence, tissue T2-
relaxivity increases due to the rapid dephasing of the spins (Gillis and Koenig, 1987). Through this 
so-called susceptibility effect, the signal from normal liver dramatically decreases after SPIO 
administration. While malignant liver foci do not contain Kupffer cells, their signal remains 
unaltered, and the signal difference between liver and lesions increases. The effective imaging 
window after a slow SPIO-infusion is from approximately 30 minutes to several hours (van Hecke 
et al., 1989). 
 
SPIO consists of iron oxide particles that are 120-180 nm in diameter. The particles are suspended 
in water, and then coated with dextran in order to form a stable compound. It is administered as a 
slow intravenous infusion. SPIO is biodegradable and the iron is eventually incorporated into 
normal iron metabolism of the body (Weissleder et al., 1989). Maximum increase in 1/T2 (i.e. T2 
relaxation rate) occurs approximately four hours after administration, and the half-time of the 1/T2 
effect is 1-2 days (Weissleder et al., 1989). The half-life of the iron is approximately 3 days. Liver 
signal normalizes after SPIO infusion within 3-7 days (Saini et al., 1987; Stark et al., 1988). 
 
SPIO-enhanced MRI has shown potential in lesion detection (Reimer et al., 2000). Several reports 
have demostrated increased lesion counts in SPIO-enhanced images at 1.0T or less (Fretz et al., 
1990; Seneterre et al., 1996; Ward et al., 2000) and in 1.5T (Winter et al., 1993; Bellin et al., 1994; 
Oudkerk et al., 1997; Müller et al., 1999; Poeckler-Schoeniger et al., 1999). However, contradictory 
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reports are available (Marchal et al., 1989; Denys et al., 1994; Duda et al., 1994). There is also 
evidence that the use of SPIO may improve lesion characterization. Focal nodular hyperplasia 
(FNH) may reliably be diagnosed with the use of SPIO (Precetti-Morel et al., 1999; Paley et al., 
2000). Double-contrast imaging with SPIO in conjunction with Gd-DTPA has also been suggested 
with favourable results (Nakamura et al., 2000; Ward et al., 2000; Kubaska et al., 2001). 
 
3.3.2 Manganese dipyridoxyl-diphosphate 
 
Manganese dipyridoxyl-diphosphate (MnDPDP) is an additional hepatobiliary contrast agent 
designed for liver tumor imaging (Young et al., 1990; Elizondo et al., 1991; Lim et al., 1991; 
Bernardino et al., 1992; Hamm et al., 1992). There is evidence of uptake of the compound to a small 
degree also by pancreas (Gehl et al., 1991), adrenal glands (Mitchell et al., 1995) and kidneys 
(Rofsky and Earls, 1996). Manganese (Mn) is a transition metal containing five unpaired electrons 
as Mn2+ ion. In order to reduce the high toxicity of manganese it is complexed to the dipyridoxyl-
diphosphate (DPDP) ligand. This ligand is a B6-vitamin derivative facilitating the uptake of the 
compound by the hepatocytes via a membrane transport system (Rofsky and Earls, 1996). MnDPDP 
(Teslascan, Nycomed, Oslo, Norway) is a stable, highly water soluble chelate. The manganese is 
eliminated from the body mainly through biliary excretion into the gut and via urinary excretion 
(Elizondo et al., 1991). 
 
MnDPDP is a paramagnetic agent, thus enhancing the T1 relaxation of normal liver parenchyma. 
The observed signal intensity of normal liver increases in T1-weighted images. Metastatic liver 
lesions do not contain hepatocytes, and their signal intensity remains unchanged. Therefore, the 
signal difference between normal liver parenchyma and metastases increases (Hamm et al., 1992). 
The effective imaging window after MnDPDP injection is from 15 minutes to several hours (Nelson 
et al., 1991). 
 
Numerous clinical studies have demonstrated the effectiveness of MnDPDP-enhanced liver MRI in 
lesion detection (Bernardino et al., 1991; Rummeny et al., 1991; Hamm et al., 1992). MnDPDP has 
also potential in lesion characterization. It has been demonstrated that MnDPDP accumulates into 
liver pathologies of hepatocellular origin such as FNH (Coffin et al., 1999) and well-differentiated 
hepatocellular carcinoma (HCC) (Ni et al., 1993). 
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3.3.3 Gadobenate dimeglumine 
 
Gadolinium benzyloxypropionictetraacetic acid (Gd-BOPTA or gadobenate dimeglumine, 
MultiHance, Bracco, Rome, Italy) is another currently available paramagnetic MR contrast agent 
with tissue-specificity. It has only 2-5% uptake into hepatocytes but more powerful effect on the T1-
relaxivity than Gd-DTPA. It may also be considered as an extracellular hepatobiliary contrast agent 
(de Haen and Gozzini, 1993). Therefore, it is a dual acting (i.e. hybrid) contrast agent with features 
of extracellular compounds for dynamic imaging and accumulation into hepatocytes for delayed 
imaging (Kirchin et al., 1998). 
 
3.4 MR contrast agents under development 
 
There are numerous different intravenous MR contrast agents under investigation. Gadolinium-
ethoxybenzyldiethylenetriaminepentaacetic acid (Gd-EOB-DTPA) is an ionic and water soluble 
gadolinium-chelate. It accumulates in the hepatocytes with approximately 50% uptake of the 
injected dose. As a paramagnetic substance it is used with T1-weighted sequences. Liver signal in 
T1-weighted images is not attenuated as much as without Gd-EOB-DTPA resulting in increased 
signal intensity in images. Gd-EOB-DTPA demonstrates a biphasic pattern of hepatic enhancement. 
At first, hepatic enhancement is unspecific reflecting liver perfusion. It is followed by the 
parenchymal phase of enhancement as the contrast agent is taken up by the hepatocytes (Reimer et 
al., 1996). 
 
In addition to hepatobiliary agents, targeted contrast media offer an alternative approach for MRI. 
Gupta and Weissleder have written a thorough review of these agents (Gupta and Weissleder, 
1996). The target may be a pathological process such as inflammation or hepatic metastasis. 
Receptor targeted compounds have been investigated (Reimer et al., 1990). Carrier molecules 
include antibodies such as monoclonal antibodies (Gupta and Weissleder, 1996), and proteins such 
as asialoglycoprotein (Reimer et al., 1991). Additionally, red blood cells have been used to transport 
magnetic labels to their destination (Johnson et al., 1998). The magnetic labels carried by the 
molecules or cells are responsible for the magnetic effects detected by MRI. These labels are metal 
ion chelates such as gadolinium, manganese, iron or dysprosium, and iron oxides such as magnetite 
or maghemite. More recently, new gadolinium-based contrast agents have been under development. 
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Such agents include macrocyclic gadolinium chelates (Marinelli et al., 2000) and gadoversetamide 
(Rubin et al., 1999). 
 
Blood pool contrast agents have also been under investigation (Adzamli et al., 1997; Johnson et al., 
1998). Ultrasmall superparamagnetic iron oxide (USPIO) are analogous to SPIO. The smaller 
particle size of USPIO when compared to SPIO (means sizes of 11.4 nm and 150 nm, respectively) 
facilitates much longer plasma half-life (approximately 81 minutes for USPIO and 6 minutes for 
SPIO) because phagocytosis is significantly slower due to the smaller size (Saini et al., 2000). Blood 
pool agents may be utilized in lesion characterization providing information about the vascular 
pattern of the tumor. There is no blood pool agent currently available for clinical use. 
 
4. MRI of Liver Tumors 
 
4.1 General considerations 
 
The first clinical liver MRI studies were carried out by Doyle et al. and Smith et al. in 1981. In their 
case report with a 0.04T MR device, Smith et al. demonstrated a liver tumor having the same T1 
relaxation time with blood and consequently, this tumor was diagnosed to be a hemangioma (Smith 
et al., 1981a). This was verified in operation. Later in 1981, Smith et al. published a liver NMR 
study with a population of 50 patients, and concluded that the specificity of MRI based on T1 
relaxation time calculations is superior to that of ultrasound and radionuclide studies (Smith et al., 
1981b). In their work, Doyle et al. (Doyle et al., 1981) studied both focal liver lesions and diffuse 
liver diseases. They found the specificity of T1 calculations to be lower than that suggested by 
Smith et al. However, they predicted that NMR may make a valuable contribution to the diagnosis 
of liver disease. 
 
Abdominal MRI has for a long time been deterred by movement artifacts from heart, pulsation of 
the abdominal vessels, peristalsis and breathing. The introduction of high field MR devices with 
breathhold imaging sequences, and the introduction of dedicated phased-array body coils have made 
abdominal MRI attractive (Hayes et al., 1992; Campeau et al., 1995). Additionally, dynamic 
gadolinium-enhanced imaging during breathhold, and the possibility to acquire thin slices have 
substantially increased the sensitivity of liver MRI. Moreover, the number of imaging techniques 
with variable imaging parameters to be selected make liver MRI a challenging method. With the 
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invention of tissue-specific contrast agents, and special imaging techniques such as MT (Wolff and 
Balaban, 1989) and SL (Sepponen, 1984), effective abdominal MRI may be performed even at low 
magnetic field strengths far below 1.0T. 
 
Focal liver lesions are frequently detected in patients undergoing abdominal investigations. These 
liver tumors constitute a major diagnostic challenge for radiological imaging especially when cancer 
patients are involved. Some liver lesions such as FNH occasionally appear isointense with liver 
parenchyma with conventional MR pulse sequences (Mortelé et al., 2000). Therefore, contrast 
manipulation or the use of contrast agents is often mandatory for the accurate determination of 
lesion count. 
 
In the differentiation between benign and malignant liver tumors various quantitative methods have 
been proposed. Differencies in the T1 or T2 relaxation times (Smith et al., 1981a and 1981b; 
Ohtomo et al., 1985; Goldberg et al., 1991; McFarland et al., 1994) or in the signal intensity ratios 
(SIR) (Itoh et al., 1990) were thought to accurately make the distinction between hemangiomas and 
metastases. The enhancement pattern with Gd-DTPA is highly specific for hepatic hemangiomas 
(Mitchell et al., 1994). Rim-enhancement with peripheral wash-out sign is indicative for a malignant 
lesion (Mahfouz et al., 1994; Mitchell et al., 1994). A number of qualitative features including the 
sharpness of lesion border (Ros et al., 1987), the signal intensity characteristics (Yamashita et al., 
1994), and the strength of signal with strongly T2-weighted sequences (Brown et al., 1991) have 
also been assigned in the characterization of liver tumors. 
 
4.2 Imaging techniques 
 
Optimal imaging protocol for liver tumor MR imaging depends on the field strength of the MR unit 
used. At low and mid-field magnetic strengths such as 0.1T or 0.5T, T1-weighted sequences are 
more sensitive in lesion detection than T2-weighted techniques (Reinig et al., 1989). Bottomley et 
al. (Bottomley et al., 1986) have demostrated that the T1 differencies between normal liver and 
tumor are reduced as the magnetic field strength increases. At higher field strengths, T2-imaging is 
more favorable (Stark et al., 1986; Foley et al., 1987). With the development of fatsuppression 
techniques, T2-weighted sequences with fatsuppression has been found effective liver MRI (Lu et 
al., 1994; Powers et al., 1994). 
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For good quality MR imaging of the liver, the coils are important. Earlier, whole-volume body coils 
were used but later, dedicated phased-array multicoil systems have been introduced (Hayes et al., 
1992). With the use of these new coils, the signal-to-noise, the lesion-to-liver contrast and thus, 
lesion detection is considerably improved (Campeau et al., 1995). Additionally, strong and fast 
gradient coils enable thin slices to be acquired during breathhold. 
 
It is obvious that a combination of sequences is required for adequate liver evaluation. In high field 
strengths, we need T2-weighted sequences for accurate lesion detection, and T1-weighted 
techniques for the depiction of anatomy, and for Gd-DTPA. Furthermore, both T1- and T2-weighted 
sequences are essential for the utilization of tissue-specific contrast agents. Finally, there are MR 
techniques such as MT and SL designed for contrast manipulation. 
 
4.3 Focal liver lesions 
 
Focal liver lesions range from benign cysts to extremely aggressive hepatocellular carcinomas and 
cholangiocarcinomas. Liver is a common site of distant metastases from a variety of cancers. The 
natural courses of these liver tumors are highly variable. Liver biopsy is often the ultimate 
conclusive diagnostic procedure but non-invasive imaging may determine lesion count and the 
nature of lesion(s) with high confidence level. MRI has shown its diagnostic power with respect to 
these demands. 
 
4.3.1 Benign liver tumors 
 
4.3.1.1 Liver cyst 
 
Liver cysts are most often found as incidental findings. As a rule, cysts are easily differentiated from 
either other benign or malignant liver lesions. They appear as homogeneous and sharply 
demarcated, non-enhancing lesions with hypointensity on T1-weighted images and strong 
hyperintensity on T2-weighted images. 
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4.3.1.2 Hepatic hemangioma 
 
The often clinically silent hepatic hemangioma is the most common solid benign liver tumor with 
the occurrence of up to 20% in autopsy material in Finland (Karhunen, 1986). It may be found at 
any age and predominantly in women. Hemangioma is usually a solitary lesion with a 
peripheral subcapsular location. Cavernous hemangiomas are comprised of blood-filled spaces or 
vascular channels lined with a single layer of endothelium separated by fibrous septa. There may be 
areas of thrombosis or fibrosis. Occasionally calcifications are present. Very slow blood flow is 
characteristic. In general, hemangiomas are stable lesions except during pregnancy when they may 
enlarge (Kinnard et al., 1995). Unless for the large size causing symptoms such as abdominal pain 
or risk of spontaneous rupture, operative treatment is not warranted. 
 
On MR images, hemangiomas appear as sharply demarcated focal lesions with homogeneous signal 
intensity. With T1-weighted sequences they appear as lesions with lower signal relative to normal 
liver parenchyma. On T2-weighted images, however, hemangiomas demonstrate a markedly bright 
signal (Brown et al., 1991). The signal intensity is characteristically of the same magnitude as that 
of the CSF (Wittenberg et al., 1988). The highly specific feature of hemangiomas is their contrast 
enhancement pattern (Mitchell et al., 1994). At early contrast uptake phase, hemangiomas show 
peripheral nodular enhancement with typical progressive fill-in with time. Complete contrast 
enhancement occurs later except for giant hemangiomas with fibrous central scar tissue. Recently, 
atypical early homogenous enhancement (Marti-Bonmati et al., 1999) or even inside-out pattern 
(Kim et al., 2000) have been reported. 
 
4.3.1.3 Focal nodular hyperplasia 
 
Focal nodular hyperplasia (FNH) is a benign tumorlike condition that is likely a hyperplastic 
response to an underlying arteriovenous malformation. If cysts are excluded, it is the second most 
common benign hepatic tumor with the occurrence of 8% in autopsy material (Karhunen, 1986). 
FNH is more common in women than in men. FNH consists of nodules of hyperplastic hepatocytes 
containing bile ductules with abundance of vessels especially in the central scar. Due to good 
vascularity, necrosis is rarely seen. In MR images, FNH usually appears as a well-circumscribed 
solitary lesion without a capsule and with homogeneous signal-intensity. The signal-intensity in 
both T1 and T2-weighted images may be close to that of the normal liver parenchyma (Mattison et 
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al., 1987). Strong early enhancement after intravenous administration of Gd-DTPA is essential in 
the MR diagnosis of FNH (Mahfouz et al., 1993). The enhancement decreases with time, and FNH 
often appears isointense with normal liver parenchyma in late gadolinium-enhanced images. 
FNH demonstrates uptake of SPIO and MnDPDP due to the Kupffer cells and normally 
functioning hepatocytes (Vogl et al., 1993; Poeckler-Schoeniger et al., 1999). Because of the lack of 
complications, FNH rarely requires surgery. 
 
4.3.1.4 Hepatic adenoma 
 
The majority of rare hepatocellular adenomas are detected in women of childbearing age, and they 
are associated with the use of oral contraceptives (Karhunen, 1986). Hepatic adenomas are 
considered to be premalignant tumors and therefore, the treatment of choice is surgery although the 
risk of conversion to malignancy is considered to be small (Gordon et al., 1986). Surgery is also 
warranted because of the possible hemorrhagic complications (Leese et al., 1988). Adenomas 
consist of neoplastic hepatocytes arranged in sheets or cords, and they often present a capsule 
containing large vessels. Areas of hemorrhage or infarction may be detected. Fatty degeneration of 
the hepatocytes is frequently seen. Adenomas lack portal and terminal hepatic veins. With MRI, 
their signal intensity is heterogenous on both T1- and T2-weighted images (Paulson et al., 1994). 
On T1-weighted images, areas of increased signal intensity relative to normal live parenchyma are 
due to fatty degeneration or hemorrhage (Arrive et al., 1994; Chung et al., 1995). Early arterial 
enhancement with extracellular contrast agents may be seen (Chung et al., 1995). MR imaging 
findings of hepatic adenomas are, however, variable and unspecific (Rummeny et al., 1989), and 
thus it is often difficult to distinguish adenoma from well-differentiated hepatocellular carcinoma. 
 
4.3.1.5 Other benign liver tumors 
 
Other more infrequent benign liver tumors include biliary hamartomas, inflammatory pseudotumor 
of the liver, lipomas, angiomyolipomas, leiomyomas, and regenerative nodules in cirrhotic livers 
and hemangioendotheliomas in children. Focal fatty degeneration may also appear as a tumorous 
mass (Kawashima et al., 1986). 
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4.3.2 Malignant liver tumors 
 
4.3.2.1 Liver metastases 
 
Liver metastases are by far the most common malignant liver tumors (Baker et al., 1995). Colon, 
breast, lungs, stomach, and pancreas are among the primary cancers frequently followed by liver 
metastases. The majority of liver metastases are hypovascular i.e. they are less vascular than normal 
liver parenchyma. These lesions are best detected during the portal venous phase of enhancement as 
the liver exhibits the strongest parenchymal enhancement. Hypervascular metastases, however, may 
be obscured during this phase (Low et al., 1993). These lesions are more vascular than normal liver, 
and they demonstrate early arterial enhancement when liver is still practically unenhanced. 
Hypervascular metastases arise from cancers originating from kidney, breast, islet cell, skin 
(melanoma), adrenal gland (pheochromocytoma), and thyroid gland. Liver metastases from 
carcinoid and sarcomas are also hypervascular. 
 
Hepatic metastases have a wide variety of appearances on MR images. On T2-weighted MR images 
metastases usually appear hyperintense relative to liver. However, their signal intensities are 
typically lower when compared to cysts or hemangiomas (Lewis and Chezmar, 1997). They have 
often heterogeneous signal intensity. On unenhanced T1-weighted images they are hypointense 
except for occasional melanoma metastases which may appear bright (Lee et al., 1992), and 
demonstrate low signal on T2-weighted images due to melanin (Lewis and Chezmar, 1997). 
Metastases demonstrate unsharp demarcation relative to surrounding liver parenchyma, and on T2-
weighted images, they may exhibit smooth central area of high signal intensity surrounded by a ring 
of lower signal intensity (so called target pattern) (Laing and Gibson, 1998). Central necrosis with 
high T2 signal intensity is commonly seen especially in expanding and large metastases. Metastases 
may also appear as a mass surrounded by a ring or wedge of high signal intensity (so called halo 
pattern) (Lee et al., 1991). This halo pattern has been attributed to peritumoral edema or peritumoral 
tumor infiltration. 
 
Metastases show heterogeneous enhancement. Rim-enhancement with peripheral washout sign in 
dynamic gadolinium-enhanced imaging has been reported to be highly suggestive to a malignant 
lesion such as metastasis (Mahfouz et al., 1994; Mitchell et al., 1994). The washout sign is seen 
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specific contrast agents render liver metastases readily detectable because they do not enhance with 
these agents as normal liver parenchyma (Hamm et al., 1992; Bellin et al., 1994). A case report, 
however, demonstrated uptake of MnDPDP by liver metastases from neuroendocrine pancreatic 
tumor (Mathieu et al., 1999). 
 
4.3.2.2 Hepatocellular carcinoma 
 
Hepatocellular carcinoma (HCC) often occurs in association with chronic liver disease such as 
cirrhosis or hepatitis (Ohtomo 1997). It is the most common primary liver malignancy. The average 
age at diagnosis is from 60 to 80 years. The evolution of HCC is thought to happen through 
regenerative nodules converting to adenomatous hyperplasia which in turn may contain atypical 
cells or even malignant cells (Arakawa et al., 1986). Regenerative nodules are a reparative response 
to cell injury in cirrhosis and adenomatous hyperplasia are markedly enlarged regenerative nodules 
(Arakawa et al., 1986). HCC may be solitary or multiple. Large masses often present daughter 
lesions and necrosis is frequently seen. HCC may invade portal veins, hepatic veins or bile ducts 
(Nakashima et al., 1983). 
 
The signal characteristics of HCC lesions is highly variable in both T1- and T2-weighted images 
(Kelekis et al., 1998). High signal on unenhanced T1-weighted image is due to intratumoral 
steatosis, copper accumulations (Ebara et al., 1986; Ebara et al., 1991) or hemorrhage (Kadoya et 
al., 1992). High signal intensity on T2-weighted images is the rule, and a mosaic pattern is often 
seen especially if the lesion is more than 3cm in diameter (Kadoya et al., 1992). High T2 signal 
intensity may be used to differentiate HCC from regenerating nodules which classically have low T2 
signal attributed to iron accumulations (Buetow and Midkiff, 1997). HCC may demonstrate strong 
enhancement with gadolinium at early arterial phase. At later phases heterogenous contrast 
enhancement appearance is most often seen which is due to hypervascularity and areas of necrosis 
(Buetow and Midkiff, 1997). It has been demonstrated that well-differentiated HCC enhances with 
MnDPDP suggesting that the fagocytic activity of the hepatocytes in this type of tumor is preserved 
(Liou et al., 1993). 
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4.3.2.3 Other primary liver malignancies 
 
Intrahepatic cholangiocarcinoma arises from the bile duct epithelium, and it is the second most 
common primary liver malignancy. Central scar tissue may be seen but hemorrhage, necrosis, and 
cystic degeneration are uncommon (Ros, 1994). Typical MR appearance is a nonencapsulated tumor 
with hypointensity on T1-weighted images and hyperintensity on T2-weighted images. On T2-
weighted images, a hypointense central scar may be seen. With dynamic gadolinium-enhanced 
imaging, small tumors may show homogeneous enhancement but in large cholangiocarcinomas 
minimal or moderate peripheral enhancement is detected with progressive and concentric filling in 
(Vilgrain et al., 1997; Worwattanakul et al., 1998). 
 
Fibrolamellar carcinoma is a rare variant of HCC with quite unique features (Berman et al., 1988). It 
is seen in non-cirrhotic livers of young population. Hemorrhage or necrosis are not typical. 
Macroscopically it resembles FNH. On MR images they are usually seen as hypointense lesions 
with T1-weighted sequences and hyperintense lesions with T2-weighted techniques. They have a 
central scar which is of low signal intensity with both T1-weighted and T2-weighted images in 
contrast to the cenral scar seen in FNHs which is bright on T2-weighted images (Ichikawa et al., 
1999). On dynamic gadolinium-enhanced images, fibrolamellar carcinoma demonstrates early 
diffuse heterogeneous enhancement and promptly thereafter the enhancement is homogeneous, and 
isointense signal intensity is noted (McLarney et al., 1999). One reported case with MnDPDP-
enhancement has been published (Ichikawa et al., 1999). 
 
Biliary cystadenocarcinoma, hepatic angiosarcoma, epitheloid hemangioendothelioma, lymphoma 
and nonvascular sarcomas such as leiomyosarcoma, malignant fibrous histiocytoma and 
fibrosarcoma represent additional but very rare primary liver malignancies. 
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PURPOSES OF THE STUDY 
 
In this thesis, focal liver lesions were investigated with the application of intrinsic and extrinsic 
methods for the manipulation of MR tissue contrast. 
 
The intrinsic contrast modifying techniques were studied at 0.1T. The potential of the multiple slice 
spin lock (SL) technique in the distinction between hepatic hemangiomas and liver metastases was 
evaluated. The specific aims were: 
 
1. To evaluate the ability of the multiple slice SL technique in the generation of 
magnetization transfer (MT)-like tissue contrast in liver and in focal liver lesions (I). 
 
2. To assess the tissue characterization potential of the multiple slice SL technique (II). 
 
The extrinsic methods were studied at the field strengths of 1.0T and 1.5T. The potential of liver-
specific contrast agents in the detection of focal hepatic lesions was investigated. The specific aims 
were: 
 
3. To investigate the sensitivity of liver-specific MR contrast agents superparamagnetic 
iron oxide (SPIO) and manganese dipyridoxyl-diphosphate (MnDPDP) in liver tumor detection. 
Especially, the performance of the short inversion time inversion recovery sequence (STIR) in 
conjunction with SPIO and MnDPDP was assessed (III, IV). 
 
4. To evaluate the lesion detection potential of the combined use of liver-specific SPIO 
and extracellular gadolinium tetraazacyclododecanetetraacetic acid (Gd-DOTA) in liver MRI (V). 
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MATERIALS AND METHODS 
 
1. Patient Population 
 
A total of 92 patients were examined in this investigation. 
 
In the Study I, twenty-seven patients with previously detected focal liver lesions were imaged. 
Fourteen patients with hepatic hemangiomas, and thirteen patients suffering from liver metastases of 
breast cancer (n=9) or colon carcinoma (n=4) were included. There were 22 women and 5 men, their 
ages ranging from 31 to 82 years (mean, 53 years). The lesion size in the hemangioma group ranged 
from 10 to 50 mm (mean, 24.4 mm), and in the metastasis group from 10 to 48 mm (mean, 20.6 
mm). Three of the hemangiomas were verified with fine needle biopsies (FNB), histological proof 
was obtained from one hemangioma, one was observed during laparotomy, and the remaining nine 
cases showed typical US and/or contrast-enhanced CT appearances with no progression during 
follow up (from 10 to 58 months, mean 16.4 months). Two of the metastatic lesions were verified 
with FNBs, and histological proof was obtained from another two lesions. The remaining nine 
metastatic lesions were detected in patients with a known primary cancer, and these lesions showed 
progression during follow up. 
 
In the Study II, sixteen patients with a known primary malignancy in the breast (n=11) or the colon  
(n=5) and with metastatic lesions in the liver, previously detected with ultrasound (US) or computed 
tomography (CT), were imaged. One of these patients had a coincidental hemangioma, which was 
included in the analysis. In addition, sixteen patients with hemangioma of the liver were 
investigated. There were thirteen women and four men in the hemangioma group, their ages ranging 
from 33 to 74 years (mean 53.8 years); and 13 women and three men in the metastasis group with 
ages ranging from 32 to 82 years (mean 57 years). The lesion size ranged from 10 to 61 mm in the 
hemangioma group (mean 23.5 mm) and from 10 to 48 mm in the metastasis group (mean 21.9 
mm). Three hemangiomas were verified with FNBs, and one was determined during laparotomy. 
The remaining thirteen lesions had typical US appearances and showed no progression during 
follow-up (study interval range from 4 to 36 months; mean 10.5 months). Three metastases from 
breast cancer were verified with FNBs; eight had a typical target lesion appearance in US. The 
previous radiological studies (US and/or CT) in these patients had been considered normal with 
respect to the liver, and these lesions showed progression during follow-up. Three of the metastases 
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from colon carcinoma were verified with histological samples; the other two lesions were 
considered as new lesions and showed progression during follow-up. 
 
In the Study III a total of 20 patients were included. One patient did not demostrate liver lesions at 
MRI. Eleven of the analyzed patients were males and eight were females (one patient did not 
demonstrate lesions in MRI). Their ages ranged from 27 to 77 years (mean, 57 years). Fifteen 
patients had metastatic disease from primary cancer of the colon (n=10), the kidney (n=3), the lung 
(n=1) or the retroperitoneum (n=1). There were one hepatocellular carcinoma and one hepatic 
hemangiosarcoma. Two patients had benign lesions: one with a hemangioma, the other 
demonstrated both a hemangioma and a focal nodular hyperplasia (FNH). The natures of the lesions 
were confirmed by biopsies with 12 patients. Clinical proof (increased carcinoembryonic antigen 
level, history of previously operated and confirmed metastases, and/or the appearance of new focal 
liver lesions not detected in previous examinations) was obtained from eight patients. In all 
metastatic cases, the type of primary malignancy had been determined from histological samples. 
 
In the Study IV, the patient population included 15 women and 5 men their ages ranging from 49 to 
76 years (mean, 62 years). Fifteen patients had metastatic liver disease (nine with primary colorectal 
carcinoma, three with primary breast carcinoma, and single cases with primary broncho-alveolar 
carcinoma, cystadenocarcinoma and cholangiocarcinoma). There were five patients with a hepatic 
hemangioma. The analyzed lesions ranged in diameter from 15 to 61 mm (mean, 30 mm). Ten of 
the metastatic cases were histologically or cytologically verified and five lesions appeared to be new 
lesions and showed progression during follow-up. Three hemangiomas were verified with fine 
needle biopsies and two had typical US appearances and showed peripheral filling-up enhancement 
chracteristics in dynamic contrast-enhanced CT. 
 
In the Study V, fourteen women and six men with ages ranging from 26 to 78 years (mean, 54 years) 
were included. Sixteen of them demonstrated focal liver lesions: there were three patients with 
FNHs, two with hemangiomas and HCCs, one patient with a cholangiocarcinoma, and nine with 
liver metastases. There was one patient with both liver metastases and hemangiomas. With the 
metastatic cases, the primary cancers were in the colon (n=6) and in the breast (n=1). Additionally, 
there were two patients with melanoma. The lesions were verified with histology (n=12) and with 
imaging findings and follow-up data (n=5). 
 32 
2. MR Imaging 
 
Clinical MR devices operating with three different magnetic field strengths were used in the studies. 
The multiple slice SL and MT experiments (I, II) were performed by using a solenoidal coil and a 
resistive whole body scanner operating at 0.1T (Merit, Picker Nordstar, Helsinki, Finland). The 
studies with tissue-specific MR contrast agents (III-V) were conducted by using superconducting 
MR systems at 1.0T (III, IV) (Magnetom 42SP; Siemens, Erlangen, Germany) and at 1.5T (V) 
(Magnetom Vision, Siemens, Erlangen, Germany). 
 
Moderately T2-weighted GE technique was employed in the multiple slice SL experiments (I-II). 
Both conventional GE and SL-GE sequences with 1500/40 ms (TR/TE, respectively) were obtained. 
A FA of 60° was used, and the slice thickness was 10 mm. There were two acquisitions (number of 
excitations, NEX=2), a 461 mm field of view (FOV), matrix (MA) size of 256x256 pixels, and time 
of acquisition (TA) of 12’48’’. The strength of B1L was 40µT and TL was 10 ms. 
 
In the MT experiments (I) conventional MT-GE sequence with following parameters was used: 
TR=1500, TE =40 ms, FA=60°, 10 mm slice thickness, NEX=2, a 461 mm FOV, MA=256x256 
pixels. The amplitude of the saturation pulse Boff was 13µT. A 4kHz frequency offset was selected 
in order to avoid direct (bleedover) effect of the off-resonance pulse on the magnetization of Hf. 
Pulse duration of 300 ms was chosen to achieve significant MT-effect in liver parenchyma. 
 
In the SPIO study (III), four MR pulse sequences were used. T1-weighted SE sequence was used 
with following parameters: TR=550 ms, TE=15 ms, NEX=6, slice thickness 8 mm with an interslice 
gap of 30%, FOV=350 mm, MA=192x256 pixels. T2- and proton density-weighted double echo SE 
sequence parameters were: TR/TEs=1900/15,90 ms, NEX=2, slice thickness 8 mm with an 
interslice gap of 30%, FOV=350 mm, and with MA=128x256 pixels. The STIR sequence was 
obtained with TR/TE/TI of 1900/20/150 ms, respectively and NEX=2, slice thickness 10 mm with 
an interslice gap of 50%, FOV=320 mm, MA=128x256 pixels. Saturation pulses were used cranial 
(all sequences) and caudal (all except the T1-weighted sequence) to the liver. 
 
 
In the MnDPDP study (IV), the T1-weighted SE images were obtained with TR=600 ms and TE=17 
ms, NEX=4, and MA=128x256 pixels. The T1-weighted breath-hold GE (fast low-angle shot, 
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FLASH) images were acquired with TR=153 ms, TE=6 ms, FA=70°, NEX=1, and MA=192x256 
pixels. The STIR images were obtained with 1900/20/150 ms (TR/TE/TI), NEX=2, and 
MA=128x256 pixels. The precontrast T2-weighted SE images were acquired with TR=1900 ms, 
TE=90 ms, NEX=2, and MA 128x256 pixels. The FOV was from 350 mm to 400 mm, and the slice 
thickness was 10 mm with all sequences. 
 
In the study V, TR=6.3 ms and TE=3.0 ms were used with the True FISP sequence. Additional 
parameters were: FA=70°, NEX=1, slice thickness=5 mm, FOV=263x350 mm, MA=192x256 
pixels and TA=13 s. The T2-weighted HASTE sequence with fatsuppression consisted of TR=4.2 
ms and TE=59 ms with FA=140°, NEX=1, slice thickness=6 mm, FOV=270x432 mm, 
MA=128x256 pixels and TA=25 s. The fatsuppressed T1-weighted sequence was used with 
following parameters: TR=85.2 ms, TE=4.1 ms, FA=70°, NEX=2, slice thickness=5 mm, 
FOV=263x350 mm, MA=140x256 pixels and TA=24 s. The fast SE-STIR sequence was used with 
a TI=180 ms. Additional parameters included TR=3250 ms, TE=85 ms, FA=180°, NEX=3, slice 
thickness=8 mm, FOV 323x430 mm, MA=150x256 pixels and TA=4 min 57 s. 
 
3. Contrast Agents 
 
Superparamagnetic iron oxide (SPIO, Endorem, Guerbet, Paris, France) was used in Studies III 
and V. It was administered at a dose of 15 µmol/kg. In the Study III, the dose used for each patient 
was 0.075 ml of particle solution/kilogram body weight (mean 5.2 ml, range 3.9 to 9.0 ml), and it 
was diluted with 100 ml of saline. The contrast medium was infused slowly at the rate of 
approximately 3-4 ml per minute into the cubital vein. The postcontrast MRI was performed from 
43 to 161 minutes (mean, 103 minutes) after the cessation of the SPIO infusion. Also in study V, a 
slow cubital vein infusion was performed. The postcontrast SPIO-enhanced MRI was conducted not 
earlier than 30 minutes after the the infusion. The doses (15 µmol/kg which is 0.075 ml of particle 
solution/kilogram body weight) ranged from 4.2 to 7.7 ml (mean, 5.5 ml). When used in conjuntion 
with Gd-DOTA, the SPIO-infusion was performed first followed by the bolus injection of Gd-
DOTA. 
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In the study IV, MnDPDP was introduced as an intravenous infusion at a dose of 5 µmol/kg body 
weight over a time period of 20 minutes (infusion rates between 1.3 and 4.3 ml/min, mean 2.0 
ml/min). Postcontrast MRI was performed 30-60 minutes after the end of the infusion. 
 
Gadolinium tetraazacyclododecanetetraacetic acid (Gd-DOTA, Dotarem, Guerbet, Paris, France) 
was used in the study V with a bolus injection into the cubital vein. A dose of 1.5 ml per kg body 
weight was administered. Then, a set of dynamic image series were acquired at 20, 40 and 60 
seconds postinjection. 
 
4. Image Analysis 
 
Only one lesion of each patient was included in the quantitative analysis, except the patients with 
two kinds of lesions (described above). In studies I-IV, signal intensities (SI) from the lesions were 
obtained by using the standard region-of-interest (ROI) technique. Representative ROIs were 
acquied from liver parenchyma, hepatic lesions and from the background noise. In studies I-III, only 
lesions ≥ 10 mm were included in the analysis in order to minimize partial volume averaging effects 
since the section thickness of most of the sequences was 10 mm. In study IV, only lesions ≥ 15 mm 
were included in the quantitative analysis. ROIs covering all except the periphery of the lesion were 
selected. Noise was measured in the phase-encoding direction ventral to the patient. The equations 
used in the calculations are provided in the Appendix. 
 
In the SPIO study (III), three radiologists independently evaluated the MR images. Total lesion 
count and the counts of lesions over and below 1 cm in diameter were assessed. In the MnDPDP 
study (IV), two radiologists evaluated the MR images. The images were evaluated by counting the 
lesions on a sequence-by-sequence basis, with separate sessions for each sequence in a randomized 
order to minimize bias for any sequence. Whether a consensus was not reached, the lesion was 
excluded from the final lesion count. In the study V, the efficacies of imaging techniques with and 
without MR contrast agents were assessed by determining the lesion counts for each technique by 
consensus reading of the MR images. 
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5. Statistical Analysis 
 
In study I, the Friedman nonparametric two-way analysis of variance (ANOVA) was used and the 
subsequent post hoc analyses were performed with the use of Student-Newman-Keuls test. 
Statistical analysis between the SL and MT effects was conducted by using the nonparametric 
Wilcoxon signed rank test, and a p-value < 0.05 was considered to indicate statistical significance. 
In the multiple slice SL experiment (II) paired Student’s t-test was used, and a p-value < 0.01 was 
considered to indicate statistical significance. 
 
In study III, the paired Student's t-test was used. A p-value < 0.01 was considered to indicate 
statistical significance. In study IV, statistical analysis was performed by using randomized blocks 
analysis of variance to compare the mean CNR values for the sequences and contrast states, using 
the patient as a randomized block. Least squares means were compared only if the overall test of the 
seven mean  CNR values for sequences combined with contrast states was significant, by using t-
tests. A t-test was also applied for the lesion count analysis. A p-value < 0.05 was considered to 
indicate statistical significance. In the study V, ANOVA was used and then, the subsequent post hoc 
analyses were performed with the use of Student’s t-test. A p-value < 0.05 was considered to 
indicate statistical significance. 
 
RESULTS 
 
1. Multiple Slice Spin Lock Technique (I-II) 
 
The SL-effects for the liver parenchyma and the liver lesions are calculated as shown in the 
Appendix. Therefore, the lower the value the greater the SL-effect and vice versa. Additionally, the 
term SL-effect indicates the magnitude of signal loss in tissue caused by the application of the 
locking pulse. 
 
The results are calculated from 32 livers with 16 hemangiomas and 16 metastases. The SL-effects of 
liver parenchyma (mean±SD=0.43±0.03, range 0.37-0.51) and liver metastases 
(mean±SD=0.43±0.06, range 0.34-0.57) were similar. The calculated SL-effects were significantly 
smaller in hemangiomas (mean±SD=0.53±0.03, range 0.46-0.61) (p < 0.0001). 
 36 
The differentiation between hepatic hemangiomas and liver metastases could be established with an 
91% diagnostic accuracy by using a cut-off value 0.5 for lesion SL-effect. 
 
2. Magnetization Transfer Technique (I) 
 
The MT-effects are calculated as shown in the Appendix. Therefore, the lower the value the greater 
the MT-effect and vice versa. Additionally, the term MT-effect indicates the magnitude of signal 
loss in tissue caused by the application of the saturation pulse. 
 
The results are calculated from 32 livers with 16 hemangiomas and 16 metastases. The MT-effects 
of the liver parenchyma were 0.54±0.07 (mean±SD; range 0.39-0.66) which were nearly the same as 
the MT-effects of the liver metastases (mean±SD=0.57±0.10, range 0.39-0.83). The MT-effects of 
the hemangiomas were greater (mean±SD=0.71±0.07, range 0.59-0.85). The difference between the 
MT-effects of hemangiomas and normal liver parenchyma was statistically significant (p<0.02) 
while the MT-effects between liver parenchyma and metastases did not demonstrate statistical 
significance (p>0.5). 
 
With a cut-off value for lesion MT-effect=0.7, the calculated diagnostic accuracy for the MT 
technique was 85% in the differentiation between hemangiomas and metastases. The SL and MT-
effects of the hemangiomas and metastases with the cut-off lines are presented in Figures 1 and 2. 
 
Figure 1. A plot demonstrating the SL-effects of the hepatic hemangiomas and liver metastases 
with the cut-off line (SL-value of 0.5). Note the small overlap between the hemangiomas and 
metastases. 
 
 
SL-effect hemangiomas
metastases
0,5
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Figure 2. A plot demonstrating the MT-effects of the hemangiomas and liver metastases with the 
cut-off line (MT-value of 0.7). Note the slightly greater overlap of the lesions when compared to the 
respective SL-effects in Fig 1. 
 
 
 
 
3. Superparamagnetic Iron Oxide (III) 
 
SPIO demonstrated a powerful effect on the signal intensity of normal liver parenchyma with the 
use of all MR sequences. The decrease in signal intensity was greatest by using conventional T2-
weighted sequence (80%). Negative hepatic enhancement (signal loss in the liver parenchyma) with 
the STIR sequence was 70%. The proton-density and T1-weighted SE sequences demonstrated 
smaller effects of 60% and 40%, respectively. The liver signal-to-noise ratios (SNR) decreased with 
all MR techniques (Table 1). The signal from liver tumors remained practically unchanged. The 
measured CNR ratios with the use of the different sequences with and without SPIO-enhancement 
are presented in Table 2. The increases in CNR when unenhanced and SPIO-enhanced techniques 
are compared to one another are also included. 
 
The numbers of detected focal liver lesions increased significantly (p<0.05) by using SPIO. SPIO-
enhanced MRI revealed 31% more lesions when compared to the precontrast MRI (106 and 81 
lesions, respectively). Especially, 28% more lesions under 1 cm in diameter were detected with the 
postcontrast MRI than with the nonenhanced MRI (59 and 46 lesions, respectively). This difference 
demonstrated statistical significance (p<0.05). 
 
MT-effect hemangiomas
metastases
0,7
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Examples of SPIO-enhanced MR images are provided in Figures 3 and 4. 
 
Figures 3a and b. (a) Unenhanced STIR image demonstrating a large mass lesion in the left liver 
lobe, and some vague hyperintensity in the right liver lobe. (b) SPIO-enhanced STIR image 
obtained from the same section level as in Fig. 3a. The large mass lesion is more clearly 
demarcated, and the small right liver lobe lesion is now easily detectable. At operation, both lesions 
proved to be metastases from kidney carcinoma. 
 
     3a.    3b. 
 
 
 
 
 
 
 
 
 
 
Figures 4a and b. (a) Unenhanced STIR image reveals a dorsally located hyperintense lesion in the 
right liver lobe. (b) SPIO-enhancement renders the lesion more conspicuous due to the signal 
blackening of the surrounding liver. At operation, the lesion proved to a metastasis from colon 
carcinoma. 
 
 
       4a.    4b. 
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________________________________________________________________________________ 
Table 1. The SNR values from liver parenchyma and liver tumors in the unenhanced and SPIO-
enhanced images (values are mean±1SD). 
 
Sequence Liver Tumor 
T1W unenhanced 
T1W SPIO-enhanced 
45±18 
24±10 
36±21 
39±20 
PDW unenhanced 
PDW SPIO-enhanced 
45±14 
19±7 
47±20 
38±14 
T2W unenhanced 
T2W SPIO-enhanced 
15±5 
3±1 
32±11 
27±9 
STIR unenhanced 
STIR SPIO-enhanced 
21±8 
6±3 
34±14 
31±14 
________________________________________________________________________________ 
 
________________________________________________________________________________ 
Table 2. The contrast-to-noise (CNR) ratios of the liver tumors in the unenhanced and SPIO-
enhanced images (values are mean±SD). 
 
Sequence Tumor CNR 
T1W unenhanced 
T1W SPIO-enhanced 
6±12 
15±13 
PDW unenhanced 
PDW SPIO-enhanced 
2±10 
18±10 
T2W unenhanced 
T2W SPIO-enhanced 
16±10 
24±9 
STIR unenhanced 
STIR SPIO-enhanced 
14±8 
25±13 
________________________________________________________________________________ 
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4. Manganese Dipyridoxyl-Diphosphate (IV) 
 
After MnDPDP administration, the T1-weighted sequences demonstrated positive parenchymal 
enhancements of 25.3±9.7% and 33.6±2.7% (mean±1SEM) for the SE and GE sequences, 
respectively. With the STIR sequence, the detected signal decrease (negative enhancement) in the 
liver parenchyma was 78.9±2.1% (mean±1SEM). The liver lesions demonstrated also slight 
enhancement with MnDPDP with mean 19.9% and 15.6% signal increases with the T1-weighted SE 
and GE sequences, respectively, and a mean signal drop of 5.5% by using the STIR sequence. 
 
The calculated CNR values for liver lesions in the pre- and postcontrast images are presented in 
Table 3. For all sequences, MnDPDP-enhanced images demonstrated significantly higher CNR 
values when compared with their precontrast counterparts (p=0.017, p=0.0001, and p=0.0001, for 
the T1-weighted SE and GE sequences, and the STIR sequence, respectively). The STIR sequence 
produced the highest increase in CNR (149.0±25.5%, mean±1SEM), whereas the CNR increased by 
58.5±12.7% and by 83.3±7.2% with the T1-weighted SE and GE sequences, respectively. Of the 
nonenhanced sequences, the T2-weighted SE sequence showed the highest mean CNR value (17.1), 
but it was significantly inferior when compared to the MnDPDP-enhanced STIR (mean CNR=30.3, 
p=0.0001) or T1-weighted GE sequence (mean CNR=21.3, p=0.026). 
 
MnDPDP increased the number of detected lesions (Table 4). The highest number of lesions was 
found with the MnDPDP-enhanced STIR sequence (58 lesions). The greatest gain in lesion count 
from pre- to postcontrast images was seen in the used T1-weighted GE sequence (31.6%), while the 
T1-weighted SE and the STIR sequences showed increases of 24.1% and 29.0%, respectively. For 
all sequences, the differencies in lesion counts between the pre- and postcontrast MRI studies were 
statistically significant (p<0.05). 
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________________________________________________________________________________ 
Table 3. The contrast-to-noise (CNR) ratios of liver tumors in the unenhanced and MnDPDP-
enhanced images (absolute values, mean±1SD). 
 
Sequence Tumor CNR 
Unenhanced T1W SE 
MnDPDP-enhanced T1W SE 
10.3±5.5 
14.8±6.7 
Unenhanced T1W GE 
MnDDP-enhanced T1W GE 
12.0±4.4 
21.3±6.6 
Unenhanced STIR 
MnDPDP-enhanced STIR 
13.9±5.6 
30.3±9.0 
________________________________________________________________________________ 
 
 
________________________________________________________________________________ 
Table 4. The numbers of lesions detected with different techniques. 
 
Sequence Unenhanced MnDPDP-enhanced 
T2W SE 32 NA 
T1W SE 29 36 
T1W GE 38 50 
STIR 45 58 
         Note: NA=not assessed 
________________________________________________________________________________ 
 
 
Examples of MnDPDP-enhanced MR images are provided in Figures 5 and 6. 
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Figures 5a and b. (a) Unenhanced T1-weighted GE image demostrates a hypointense lesion in the 
right liver lobe, and some vague hypointensity in the caudate lobe as well. (b) In the MnDPDP-
enhanced image these lesions are more readily detectable. Colon carcinoma metastases were found 
at surgery. 
 
 
        5a.    5b. 
 
 
 
 
 
 
 
 
 
 
 
Figures 6a and b. (a) In this STIR image, a large and relatively homogeneously hyperintense mass 
lesion is seen in the right liver lobe. (b) In the MnDPDP-enhanced STIR image the same lesion in 
barely visible. The finding suggests MnDPDP-uptake of the lesion and thus, a tumor of 
hepatocellular origin. At surgery, a well-differentiated hepatocellular carcinoma was found. 
 
 
        6a.    6b. 
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5. Combined Use of Superparamagnetic Iron Oxide and Gadolinium (V) 
 
The numbers of liver lesions and the respective sensitivities with sequence-by-sequence basis are 
presented in Table 5. SPIO-enhanced imaging showed the greatest number of lesions (n=58, 95% 
sensitivity). Unenhanced MRI demonstrated 55 lesions (90% sensitivity). Gadolinium-enhanced 
MRI with fatsuppressed T1-weighted sequence with or without SPIO was clearly inferior with 
lesion counts of 49 and 47, respectively. The combined use of gadolinium and SPIO showed only 
two additional lesion not seen in gadolinium-enhanced images. 
 
From single sequences, the best performance was seen with the SPIO-enhanced fast spin-echo (fSE) 
STIR (TR/TE/TI=3250/85/180 ms, respectively) sequence which detected 56 of the 61 lesions (92% 
sensitivity). Unenhanced fSE STIR and SPIO-enhanced fatsuppressed T2-weighted techniques had 
sensitivities of 89% and 90%, respectively. SPIO-enhancement did not significantly increase the 
number of detected lesions with any sequence except with the True FISP technique (p<0.05) which 
demonstrated an increase of 15% in lesion count (43 and 51 lesions in the nonenhanced and SPIO-
enhanced techniques, respectively). The SPIO-enhanced True FISP sequence had a sensitivity of 
84% for lesion detection. 
 
________________________________________________________________________________ 
Table 5. The numbers of focal liver lesions with different techniques. The sensitivities (in %) 
are shown in brackets. The sensitivities are calculated assuming that the overall lesion count is 61. 
 
Sequence Unenhanced Gd SPIO SPIO and Gd 
True FISP 43 (70) NA 51 (84) NA 
fatsuppressed T2 52 (85) NA 55 (90) NA 
fatsuppressed T1 42 (69) 47 (77) 42 (69) 49 (80) 
fast-SE STIR 54 (89) NA 56 (92) NA 
Total count 55 (90) 47 (77) 58 (95) 49 (80) 
Note: NA=not applicable 
________________________________________________________________________________ 
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DISCUSSION 
 
Focal hepatic lesions are commonly discovered during routine radiological examinations. Not only 
the detection of metastases, but also the determination of their number are important when cancer 
patients, especially those with colorectal malignancies, are evaluated. Additionally, it is essential to 
distinguish a benign hepatic lesion from a malignant one because of their different clinical 
implications. Current improvements in liver surgery, and local invasive therapies with a curative 
potential put imaging into highlight when evaluating patients with liver metastases. Liver tumor 
imaging beholds two equally important tasks: there is a need for effective lesion detection (high 
sensitivity), and a desire for accurate tumor characterization (high specificity). 
 
The radiology of liver tumors has gone through a radical change over the last decade with the 
introduction of abdominal MRI, and with the development of new CT techniques such as 
multidetector systems. MRI is currently considered to be the most accurate noninvasive method in 
the evaluation of liver lesions (Semelka et al., 1997; Reimer at al., 2000). The utilization of tissue-
specific contrast agents such as SPIO or MnDPDP, and the possibility to employ MR techniques 
that alter tissue-contrast such as MT and the multiple slice SL render MRI an attractive tool for liver 
imaging. 
 
1. Lesion Characterization 
 
In MR imaging, multiple sequences are required for accurate lesion characterization. A magnitude 
of research has been focused on finding methods for reliable differentiation between various liver 
foci. Nevertheless, liver biopsy is still sometimes warranted, especially if surgery is planned. 
 
In the early days of clinical liver MRI, T2 relaxation time differencies (Ohtomo et al., 1985; 
Goldberg et al., 1991) or differencies in the SIR (Egglin et al., 1990; Itoh et al., 1990) were thought 
to resolve the problem of the differentiation between malignant and benign lesions. Later, at 1.5T 
the difference in T2 relaxation rate with a 112ms cutoff value was found to yield a 92% sensitivity, 
and an accuracy of 97% in the discrimination of hemangiomas and malignant liver tumors 
(McFarland et al., 1994). Goldberg et al. found no overlap in the T2-values between hemangiomas 
and metastases  
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with ultrafast MR imaging (Goldberg et al., 1998). Tang et al. detected the CNR values of 
hemangiomas and cysts to be significantly higher than those of metastases with no overlap (Tang et 
al., 1998). Additionally, a variety of different MR features such as lesion signal characteristics 
(Brown et al., 1991; Tang et al., 1998) or contrast uptake patterns (Mathieu et al., 1991; Mitchell et 
al., 1994) have also been proposed in the lesion differentiation. 
 
1.1 Multiple slice spin lock technique 
 
MT has shown potential in the discrimination between benign and malignant liver lesions (Outwater 
et al., 1992; Loesberg et al., 1993). We detected similar results with the use of the multiple slice SL 
technique. The SL-effects from normal liver and liver metastases were nearly equal. However, the 
measured SL-effects from normal liver parenchyma, hemangiomas and hepatic metastases were 
greater when compared to the respective MT-effects. Furthermore, there was a definite difference 
between the MT- and SL-effects obtained from hemangiomas. Our results suggest that, in a low-
field environment, the multiple slice SL technique can be used in the differential diagnosis between 
hemangiomas and metastases similarly to MT, but the SL technique is more efficient in generating 
MT-like tissue contrast than conventional MT based sequence. Additionally, with the SL technique 
T1 dispersion studies can be performed (Lamminen et al., 1993; Markkola et al., 1996). 
Therefore, it may be assumed that the multiple slice SL technique may provide better potential for 
tissue characterization than the MT technique in liver tumor imaging. 
 
In our studies with the multiple slice SL technique, there was little overlap in the SL-effects 
between the hemangiomas and metastases (Figure 1.). With a SL-effect cut-off value of 0.5, the 
distinction between hemangiomas and metastases could be made with a 91% diagnostic accuracy. 
With the MT technique, the overlap was greater (Figure 2.) and the diagnostic accuracy lower 
(85%). Our results with the multiple slice SL technique at 0.1T are comparable with previous 
studies that were conducted at high magnetic field strengths (Itai et al., 1985; Ohtomo et al., 1985; 
McFarland et al., 1994). It may be assumed that the utilization of T1 relaxation at a very low field 
strength with the SL technique (T1ρ relaxation) contributes to the differentiation of macromolecular 
tissue (metastases) and blood-containing spaces (hemangiomas), as macromolecule-water 
interactions are better observed at very low field strengths. Also, the differencies in proton T1 
relaxation rates between blood and liver tissue increase when the effective field strength is 0.1T or 
lower (Koenig et al., 1984). 
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Our multiple slice SL studies were performed at 0.1T field-strength. It may be assumed that the 
favourable results thus obtained could be further improved in higher field strengths with higher 
SNRs. At 0.1T, specific absorption rate (SAR) was not a problem (0.084 W/kg). Because SL 
technique utilizes short pulses, it may be expected that SAR would not limit the use of SL in higher 
fields. 
 
1.2 Superparamagnetic iron oxide and manganese dipyridoxyl-dophosphate 
 
Hahn et al. have reported that by using SPIO, postcontrast lesion signal reductions of over 40% are 
characteristic for benign lesions (Hahn et al., 1992). It has been shown that FNH demonstrates 
uptake of SPIO (Precetti-Morel et al., 1999; Paley et al., 2000). In our series with SPIO, two 
hemangiomas and one FNH were included. In our solitary case of FNH, the reduction in lesion 
signal intensity in the T2-weighted SE (TR/TE =1900/90 ms) images was 36%, and the decrease 
was 59% by using the STIR sequence (TR/TE/TI=1900/20/150 ms). With two hemangiomas, 
similar findings were detected. In our study population, malignant liver foci did not demonstrate 
significant changes in signal intensities. 
 
The accumulation of MnDPDP in liver lesions of hepatocellular origin is well-documented (Ni et 
al., 1993; Rofsky et al., 1993; Coffin et al., 1999). This may serve as a basis for lesion 
characterization. In our series with MnDPDP, we included one case of histologically verified well-
differentiated HCC. This lesion demonstrated considerable contrast uptake with signal intensity 
increase of 50% in both SE (TR/TE=600/17 ms) and GE (TR/TE=153/6 ms) T1-weighted images, 
and a signal reduction of 69% in the STIR (TR/TE/TI=1900/20/150 ms) images. However, hepatic 
metastases from endocrine cancers have also demonstrated MnDPDP-uptake (Wang et al., 1998). 
 
2. Lesion Detection 
 
Numerous investigations have been conducted to compare the sensitivities of different imaging 
techniques in the detection of liver tumors (Rummeny et al., 1992; Ohlsson et al., 1993; Semelka et 
al., 1999). Research has been devoted to improve the effectiveness of any technique to increase the 
detection rate. In MRI, the use of various contrast agents has been the focus over the past decade. 
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2.1 Superparamagnetic iron oxide 
 
CNR values reflect lesion conspicuity (Tsang et al., 1988). The higher the CNR, the more readily 
detectable the lesion is. Therefore, it may be considered as a measure of the effectiveness of a pulse 
sequence in lesion detection. Multiple reports have shown that CNR is improved by SPIO 
administration and thus, more lesions are detected (Fretz et al., 1990; Bellin et al., 1994; Oudkerk et 
al., 1997). Moreover, it has been shown that SPIO-enhanced MRI is superior to unenhanced MRI or 
contrast-enhanced CT in lesion detection (Lencioni et al., 1998; Hammerstingl et al., 1999; Müller 
et al., 1999; Poeckler-Schoeniger et al., 1999; Schultz et al., 1999; Reimer et al., 2000; Ward et al., 
2000). SPIO increases the detection rate of focal lesions with cirrhotic patients (Hammerstingl et al., 
2000). Our results with SPIO are in agreement with earlier studies, and investigations performed 
afterwards. The signal intensities obtained from normal liver parenchyma were significantly lower 
in the postcontrast images with all used pulse sequences. The greatest effect was seen with the T2-
weighted SE sequence with signal reduction of 78%. Because SPIO had only slight effects on the 
signal intensity of the malignant lesions, the CNR values of liver lesions were significantly 
increased with all pulse sequences. Hence, postcontrast MRI demonstrated considerably greater 
number of lesions than the precontrast studies (n=106 and 81, respectively). Additionally, greater 
number of small lesions under 1 cm in diameter was detected (n=59 and 46, respectively). 
 
As seen from our study III and supported by literature, at field-strengths of 1.0T or lower, SPIO 
clearly depicts a greater number of lesions than seen in plain images (Fretz et al., 1990; Seneterre et 
al., 1996; Ward et al., 2000). Contradictory reports, however, are available (Marchal et al., 1989; 
Denys et al., 1994; Duda et al., 1994). In our study at 1.5T (V), SPIO slightly increased the number 
of detected liver lesions but no statistical difference could be established (p=0.77). However, the 
highest number of lesions was seen with SPIO-enhanced imaging. 
 
2.2 Manganese dipyridoxyl-diphosphate 
 
There are several investigations demonstrating the efficacy of MnDPDP in liver tumor MRI (Young 
et al., 1990; Hamm et al., 1992; Aicher et al., 1993; Federle et al., 2000b). MnDPDP is considered 
to be a T1-contrast agent, and it has been found more effective in conjunction with T1-weighted GE 
sequences when compared with SE techniques (Wang, 1998). With the imaging parameters we 
used, our findings are in accordance with mean liver signal enhancements of 33.6% and 25.3% with 
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the use of GE (TR/TE=153/6 ms) and SE (TR/TE=600/17 ms) sequences, respectively. This 
allowed us to detect significantly (p<0.05) greater number of lesions with the T1-weighted GE 
sequence (n=50) when compared with the SE technique (n=36). We believe that this difference may 
partly be explained with the fact that the GE sequence used in our study was a breathhold sequence 
thus reducing the movement artefacts. However, with both T1-weighted sequences, the number of 
detected liver lesions was significantly greater with the MnDPDP-enhanced imaging than with the 
non-enhanced studies (p<0.05). 
 
The hepatic enhancement with MnDPDP has demonstrated variability. An experimental dose of 50 
µmol/kg MnDPDP with T1-weighted sequences at 1.5T resulted in hepatic enhancement of up to 
105% (Young et al., 1990). Marchal et al. detected mean relative enhancement of 52.5% with a dose 
of 0.025 mmol/kg at 1.0T (Marchal et al., 1993). We observed a mean hepatic enhancement with 
the T1-weighted SE and GE sequences of 25.3% and 33.6%, respectively. This is less than 
previously reported. Our finding may have several explanations. First, the sensitivity of a T1-
weighted MR sequence for paramagnetic contrast agents is related to field strength as previously 
shown with gadopentetate dimeglumine (Chang et al., 1994). MnDPDP studies have been 
performed at different field strengths ranging from 1.0T to 1.5T. Our study was conducted at 1.0T 
resulting to less enhancement than at 1.5T. Secondly, Liou et al. demonstrated that the lower the 
administered dose of MnDPDP, the less enhancement is observed (Liou et al., 1993). We used a 
patient dose of 5 µmol/kg while doses of 8, 12, or even 50 µmol/kg have been used in previous 
studies with greater enhancement values. Finally, our T1-weighted SE sequence with a TR=600ms 
and TE=17ms was not as strongly T1-weighted as those used by other investigators. 
 
The combined capability of accurate lesion detection and potential to lesion characterization renders 
MnDPDP an attractive method to evaluate patients with known hepatic tumors. 
 
2.3 The short inversion time inversion recovery sequence 
 
The STIR sequence was introduced to clinical MRI by Bydder et al. in 1985 (Bydder et al., 1985a; 
Bydder et al., 1985b). The technique has been found to be sensitive in the detection of abdominal  
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malignancies, and other pathological processes in tissues (Dwyer et al., 1988; Lamminen et al., 
1994). However, there are few reports available of the use of the STIR technique in conjunction 
with liver-specific contrast agents such as SPIO and MnDPDP. In a study performed at 0.6T, Fretz 
et al. found the STIR sequence to have low SNR and CNR, with and without the use of a contrast 
medium (Fretz et al., 1989). However, with the parameters used in our study at 1.0T with SPIO, the 
CNR obtained with the STIR technique was the highest of all contrast-enhanced sequences, and 
measured contrast enhancement was second only to the T2-weighted SE sequence. The difference in 
results might be explained by the different field strenght and different imaging parameters. 
Moreover, we used presaturation pulses to reduce motion artifacts also with the STIR sequence, 
which is not reported in their study. 
 
From our results can be concluded that it is feasible to suppress signal in MnDPDP-enhanced liver 
tissue with the use of the STIR sequence. The number of detected lesions was superior to other 
sequences with or without MnDPDP-enhancement. Negative hepatic enhancement was markedly 
greater with the STIR technique than the positive enhancement obtained with either of the T1-
weighted sequences. MnDPDP-enhanced STIR imaging displayed significantly higher lesion-to-
liver CNR values than any other sequence. Our findings are supported by experimental data from 
Mühler et al (Mühler et al., 1992). Their investigation demonstrated the effectiveness of an 
experimental hepatocyte-targeted paramagnetic gadolinium chelate Gd-EOB-DTPA in the MR 
imaging of focal liver lesions in rats. By utilizing the STIR sequence at 2.0T with Gd-EOB-DTPA, 
Mühler and his colleagues achieved a negative hepatic enhancement of more than 80%. With 
MnDPDP, we measured a mean signal decrease of 79% by using the STIR sequence. The signal 
decline of MnDPDP-enhanced hepatic parenchyma in the STIR images can be explained with the 
increased relaxation rate. The value of the null point (intercept of the T1 relaxation curve and the T1 
axis) for the T1 relaxation curve of MnDPDP-enhanced liver parenchyma approaches the null point 
of fat tissue. 
 
2.4 Combined use of superparamagnetic iron oxide and gadolinium 
 
Although Gd-enhanced T1-weighted sequences are beneficial in the characterization of liver lesions 
(Hamm et al., 1994; Mahfouz et al., 1994), they have only negligible effect on the detection rate 
(Hamm et al., 1992). On the other hand, SPIO is primarily a T2-contrast agent, and has little  
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contribution on the conspicuity of hepatic lesions in T1-weighted images. The results of our double 
contrast investigation (V) indicate that the simultaneous use of SPIO and gadolinium does not 
increase the effectiveness of liver MRI. Only two additional lesions were detected with combined 
use of SPIO and Gd-DOTA by using fatsuppressed T1-weighted SE (TR/TE=85.6/4.1 ms) sequence 
when compared with only Gd-enhanced imaging (Table 5).  
 
T2-weighted sequences are considered to be the most sensitive techniques in the MRI of liver 
tumors (Rummeny et al., 1992). Our results in study V are in agreement with these previous 
findings. Unenhanced fatsuppressed T2-weighted gradient echo sequence (Half-Fourier Acquisition 
Single-shot Turbo spin-Echo, HASTE) (TR/TE=4.2/59 ms) demonstrated the second greatest 
number of lesions among the unenhanced sequences (n=52, 85% sensitivity). SPIO-enhancement 
slightly increased the lesion count (n=55, 90% sensitivity). The best performance (n=56, 92% 
sensitivity) was achieved with the SPIO-enhanced fast SE-STIR sequence (TR/TE/TI=3250/85/180 
ms). The STIR technique has previously been been shown to be highly sensitive to pathological 
conditions such as liver tumors (Paulson et al., 1994) and our results agree with the these findings. 
 
With fatsuppressed T2-weighted sequence, all image information is acquired after a single 
excitation pulse, which is followed by a long train of refocusing RF-pulses. Images with good 
resolution and with negligible motion artifacts may be obtained. With the True FISP (Fast Imaging 
with Steady state free Precession), the FISP and PSIF (reverse FISP) echoes are produced at the 
same time, so only one combined signal is received. FISP produces images with T1/T2 contrast due 
to the preserved transverse magnetization component and PSIF produces images with heavy T2-
weighting due to the very long echo times. With fast spin echo (SE)-STIR, a train of echoes follows 
each excitation pulse. Fast SE-STIR requires fewer TRs and TIs to acquire a given amount of data. 
Therefore it is more efficient than conventional SE-STIR. With fast SE-STIR, longer effective echo 
times (TEeff) are practical because it allows more signal averaging than conventional SE-STIR. If 
long TEeff is used, fast SE-STIR images are heavily T2-weighted in addition to the T1 contrast 
inherent in STIR techniques. 
 
According to our investigation, double-contrast MRI with SPIO and gadolinium was not beneficial. 
If only T1-weighted images are evaluated, Gd-enhancement increased the number of detected liver  
 51 
lesion from 42 to 47. However, Gd-enhanced MRI did not reveal any additional lesions in 
comparison with the unenhanced T2-weighted sequence. Our finding is supported by a recent report 
by Hamm et al. (Hamm et al., 1997). They concluded that at 1.5T unenhanced MRI is as sensitive in 
the detection of liver lesions as Gd-enhanced imaging. Our results indicate that unenhanced T2-
weighted sequences outnumber T1-weighted sequences either with or without gadolinium in lesion 
detection. Despite the negligible results, it may be assumed that double-contrast MRI with increased 
detection potential in conjunction with the good lesion characterization capabilities of the contrast 
agents renders the technique attractive to liver MRI. This assumption is supported by the recent 
investigation by Kubaska et al. (Kubaska et al., 2001) in which the good lesion characterization 
capability of gadolinium was shown to maintain after SPIO administration. 
 
3. Safety of Contrast Agents 
 
The overall rate of side-effects of gadolinium is low (Nelson et al., 1995). We did not detect any 
side effects with the use of Gd-DOTA. 
 
The adverse reactions of SPIO are well established, the occurrence ranging from 6.1 to 10.3% 
(Laniado and Chachuat, 1995). Low back pain is the most commonly reported side-effect. In the 
present thesis, SPIO was administered to 40 patients. Side-effects were recorded with six patients 
(15%), one of them being an anaphylactic reaction which could be related to the contrast agent. Five 
patients complained lumbar pain. 
 
A recent investigation reports an adverse reaction rate of 23% with the use of MnDPDP (Federle et 
al., 2000a). The most commonly reported adverse events were nausea and headache. The 
investigators state that most of these mild side-effects were not drug related and did not require 
treatment. The incidence of serious adverse reactions was lower (1.6%), and not drug related. In our 
study group of 20 patients, however, we did not detect any side-effects. The difference in adverse 
events may be explained with the different injection rates. Federle et al. used an injection over one 
minute and we administered the MnDPD-solution with an approximately 20 minute infusion. 
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4. Liver MRI: current trends and look into the future 
 
Liver-specific contrast agents have definitively improved the performance of liver MRI especially 
when non-cirrhotic livers harboring focal lesions are in question. The contrast agent research still 
pursues for targeted and more effective agents with a safe profile. High-field MR systems of 1.5T 
have been advocated for liver MRI. Furthermore, even field strengths of 3.0T are in clinical use for 
neuroradiology but yet not utilized in liver MRI. With high-field MR imagers, breathhold scanning 
with very short TE’s may be performed. Movement artefacts are essentially reduced. Higher spatial 
resolution is also obtained. The developments in coil technology even further increases the 
capabilities of MRI in the quest for effective liver tumor imaging. 
 
Although gadolinium has shown great potential in the diagnosis of liver hemangiomas, focal 
nodular hyperplasias and hepatic metastases, there are still uncertainties especially when small 
lesions are considered. The characteristic T2-hyperintensity and Gd-enhancement patterns of 
hemangiomas may be similar with liver metastases especially when small lesions are concerned. 
The True FISP sequence has shown potential in the characterization of liver lesions demonstrating 
small and large liver cysts and hemangiomas as markedly bright lesions while practically all 
malignant liver foci appear only slightly hyperintense or isointense with respect to normal liver 
parenchyma. 
 
Originally, SPIO was designed for T2-weighted MRI in order to increase the conspicuity and hence, 
detection rate of focal liver lesions. However, recent investigations have expanded the utility of 
SPIO towards the characterization of liver lesions. SPIO-enhanced MRI with the use of T1-
weighted sequences has been found helpful with this respect (Kim et al., 2002). Additionally, the T1 
effects of SPIO, given as a bolus for dynamic imaging, have proved to be useful in the diagnosis of 
liver hemangiomas (Sahani et al., 2002). 
 
Interventional MRI is emerging (Ojala el al., 2002). In future, liver lesions with important clinical 
implications may be the target of MRI-guided biopsy. Magnetic resonance spectroscopy (MRS) is 
evolving. To date, it is valid in the evaluation of diffuse liver diseases such as fatty degeneration 
(Ryysy et al., 2000). Its role in focal liver lesions remains to be assessed. 
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Liver MRI is under a continuous progress. This means better coils, higher magnetic field strengths 
with the capability of motion ’freezing’, and above all, advanced techniques for increased lesion 
detection and improved characterization potential. The multiple slice SL technique may play a role 
in lesion characterization even in high magnetic field strengths because the SAR is not 
compromized. Liver-specific contrast agents play a special role when evaluating patients with liver 
lesions, especially when invasive treatment is considered. 
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CONCLUSIONS 
 
1. The multiple slice SL technique provides improved tissue contrast in liver MR when 
compared to conventional MT imaging. 
 
2. The multiple slice SL MR imaging technique showed high diagnostic accuracy in the 
differentiation of hepatic hemangiomas and liver metastases. The results were comparable or even 
superior to the magnetization transfer (MT) technique. 
 
3. More lesions can be detected with superparamagnetic iron oxide (SPIO)- and 
manganese dipyridoxyl-diphosphate (MnDPDP)-enhanced MRI when compared with unenhanced 
imaging because of a considerable increase in the lesion CNR values. The short inversion time 
inversion recovery (STIR) sequence proved to be the most effective sequence in the lesion detection 
with both tissue-specific contrast agents. 
 
4. Double contrast MRI, i.e. combined use of SPIO and Gd-DOTA, did not increase the 
sensitivity of lesion detection at 1.5T. The fast SE-STIR sequence demonstrated the best 
performance in this investigation (V). 
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SUMMARY 
 
Imaging of liver diseases, especially focal liver lesions, has progressed enormously with the 
development of MRI technology and contrast agents. Modern MRI with update sequences and 
contrast agents is noninvasive and highly accurate in examining patients with known or suspected 
liver lesions, even at low-field strengths. Our results demonstrated that the lesion characterization 
potential of the multiple slice spin lock (SL) technique at 0.1T was comparable to investigations 
performed at considerably higher field strengths. 
 
The multiple slice SL technique provides tissue contrast characteristics similar to that of the 
magnetization transfer (MT) technique. However, the ability in tissue discrimination facilitated by 
the locking pulse taking advantage of very low magnetic field strength even exceeds that of the MT 
technique as shown by our results. The capability of distinguishing hepatic hemangiomas and liver 
metastases at 0.1T gave promising results with the multiple slice SL technique. This technique may 
also be employed in higher magnetic field strengths. 
 
Contrast agents provide another tool for improving the performance of MRI in liver lesion detection 
and characterization. Tissue-specific agents such as superparamagnetic iron oxide (SPIO) and 
manganese dipyridoxyl-diphosphate (MnDPDP) are specifically designed for liver lesion detection. 
Our studies demonstrated that the use of SPIO and MnDPDP improved lesion detection. The 
implementation of the STIR sequence in conjunction with these agents proved to be useful. 
Although these agents have provided controversial data at different MR field strenghts, their impact 
on lesion detection is considerable at least with field-strength of 1.0T. 
 
Double-contrast MR imaging is emerging. The idea of differently acting contrast agents is attractive, 
and recent literature has provided encouraging results. Our results at 1.5T with superparamagnetic 
iron oxide (SPIO) and gadolinium were negligible when lesion detection is considered. The 
discrepancy between earlier studies and our results may be due to different patient population. We 
included only non-cirrhotic patients while cirrhotic patiens have been evaluated earlier. Therefore it 
may be assumed that in the future, double-contrast liver MRI may play an important role in the 
further evaluation of patients with liver lesions. 
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In conclusion, the studies included in the present thesis have demonstrated the feasibility of contrast 
modifying techniques in the detection and characterization of liver lesions. The combined use of 
SPIO and gadolinium at 1.5T proved to be of negligible benefit in the detection of liver lesions. 
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APPENDIX 
 
The equations used in the investigations included in the thesis are described below. 
 
Studies I and II. The signal intensity (S) provided by the multiple slice SL sequence when 
gradient echo technique is used and the number of slices is large, and the flip angle small or 
intermediate may be calculated as follows: 
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where M0 is the net magnetization, TD is the period between successive locking pulses, and TL is 
the length of the locking pulse. 
 
The SL-effect (ESL) was calculated as follows: 
 
ESL = SISL-GE/SIGE, 
 
where the SISL-GE and SIGE are the signal intensities obtained from the multiple slice SL and GE 
images, respectively. 
 
The MT-effect (EMT) was determined by using follwing equation: 
 
EMT = SIMT-GE/SIGE, 
 
where SISL-GE, SIGE, and SIMT-GE are the signal intensity values obtained from the respective MR 
images. 
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The diagnostic accuracies for the multiple slice SL and single slice MT techniques were detemined 
as follows: 
 
The lesions falsely above or below the cut-off value were divided by all lesions included. 
 
Study III. The SNR values for the liver parenchyma and the hepatic lesions were calculated 
followingly: 
 
  SNR=SIliver/SDnoise and SNR=SIlesion/SDnoise , 
 
where SIliver and SIlesion are the signal intensity values from the liver and the lesions, respectively and 
SDnoise is the standard deviation of the background noise. The CNR ratios were obtained by using 
the following equation: 
 
  CNR=(SIlesion-SIliver)/ SDnoise. 
 
Enhancement was defined with the equation: 
 
  (SNRpre- SNRpost)/SNRpre, 
 
where SNRpre and SNRpost are the signal-to-noise ratios in the precontrast and postcontrast images, 
respectively. 
 
Study IV. Hepatic enhancement (E%) was defined as follows: 
 
  E(%)=[(SNRpost-SNRpre)/SNRpre]x100, 
 
where SNRpre and SNRpost are the signal-to-noise ratios in the corresponding pre- and postcontrast 
images. 
 
The CNR values were calculated similarly as in the Study III. 
